Interferon therapy for patients more than 60 years of age with chronic hepatitis C

J Gastroenterol Hepatol. 1995 May-Jun;10(3):246-9. doi: 10.1111/j.1440-1746.1995.tb01088.x.

Abstract

Nineteen patients aged > 60 years with chronic hepatitis C (CHC) received interferon (IFN) therapy and a complete response (CR) was achieved by five of them (26%). The incidence of CH with severe fibrosis in this elderly group was significantly higher than in another 52 patients with CHC who were < 60 years of age (the younger group; P < 0.05). There was no significant difference in the hepatitis C virus (HCV) genotype distribution between the elderly group and the younger group. However, the HCV-RNA titre was significantly higher in the elderly group than in the younger group (P < 0.05). There was no significant difference in the efficacy rate of IFN in the elderly and younger groups after standardization of the background factors. In the elderly group, the HCV-RNA titre was significantly lower in the patients achieving CR than in those with no response (P < 0.05). These data suggest that elderly patients with a low HCV-RNA titre can still respond well to IFN therapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Age Factors
  • Antiviral Agents / therapeutic use*
  • Case-Control Studies
  • Chronic Disease
  • Female
  • Hepacivirus / isolation & purification
  • Hepatitis C / epidemiology
  • Hepatitis C / therapy*
  • Hepatitis C / virology
  • Humans
  • Interferon Type I / therapeutic use
  • Interferon-alpha / therapeutic use
  • Interferons / therapeutic use*
  • Male
  • Middle Aged
  • RNA, Viral / analysis
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon Type I
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Interferons